SIHUAN PHARM (00460) announced that to promote the deep application and industrialization of artificial intelligence (AI) technology in medical aesthetics product research and development, the group has signed a framework agreement with Shenyuanzhi Pharmaceutical Biotechnology (Beijing) Co., Ltd. The two parties will jointly establish an AI R&D company led by SIHUAN PHARM to explore AI-driven development of innovative medical aesthetics products. This move marks the substantial phase of the group's strategic positioning in the "AI + medical aesthetics" innovation track.

In October 2024, the Nobel Prize in Chemistry was awarded to David Baker and two other experts who made pioneering contributions to AI protein structure research. This achievement represents not only the highest academic recognition of AI technology's empowerment in R&D, but also indicates that AI will become the core driving force for reconstructing R&D paradigms and breaking through traditional R&D bottlenecks. Under this industry trend, the collaboration between SIHUAN PHARM and Shenyuanzhi Pharmaceutical focuses on the core direction of "high-end medical aesthetics raw material innovation," aiming to build R&D barriers through technological synergy and capture the strategic commanding heights of medical aesthetics innovation.

The core of this cooperation is the deep integration of "resources + technology." SIHUAN PHARM contributes its more than 20 years of industry resources, commercialization channels, and R&D pipeline reserves in the medical aesthetics field, while Shenyuanzhi Pharmaceutical provides its independently developed Automated Design Platform for Structural Enhancement (ADPSE) and core technologies. Together, they will build a "dry-wet loop" R&D platform of "AI design - high-throughput experimental verification - data feedback iteration," enhancing the group's medical aesthetics business value in two aspects:

1. Breaking through raw material bottlenecks and upgrading medical aesthetics business: Leveraging Shenyuanzhi Pharmaceutical's proprietary protein design platform and codon design technology (NatCodon), the partnership will address the design, optimization, and expression challenges of core injectable medical aesthetics raw materials such as recombinant collagen, silk protein, and spider silk protein. This will break dependence on imported high-end raw materials and promote the upgrade of the group's medical aesthetics products toward "high-end and domestic production," consolidating market share and brand influence.

2. Reducing costs and increasing efficiency while accelerating medical aesthetics R&D processes: Using deep generative models and large language models as the core, combined with high-throughput experimental verification systems, the partnership will shorten the early R&D molecular screening cycle in the medical aesthetics field, reduce development costs for medical aesthetics candidate raw materials and products, improve R&D success rates, and strengthen the group's pipeline advancement advantages in medical aesthetics innovation competition.

SIHUAN PHARM will use the AI R&D company established through this cooperation as the core to continuously deepen AI deployment in the medical aesthetics R&D field, focusing on the development of globally pioneering raw materials and products in the medical aesthetics sector. Through technological innovation and sub-platform synergy, the company aims to address unmet needs in the medical aesthetics market, inject momentum into the long-term development of the group's medical aesthetics business, and further enhance core competitiveness and market value in the medical aesthetics industry.